BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2024.
The report offers a comprehensive look at the Company's ESG approach and showcases accomplishments in three main pillars:
In 2024, we achieved key milestones in our ESG journey, including:
To learn more about Azenta's commitment to ESG efforts, view the report in full at https://investors.azenta.com/esg.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.
"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Other forward-looking statements include but are not limited to statements about our ability to meet our ESG commitments, including GHG emission targets. Factors that could cause results to differ from our expectations include the following: our ability to reduce our environmental footprint, our ability to ensure the safety, quality and reliability of our products and our ability to monitor and assess our supply chain; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Sherry Dinsmore
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$31.76 |
Daily Change: | 0.98 3.18 |
Daily Volume: | 944,900 |
Market Cap: | US$1.450B |
May 13, 2025 November 12, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load